Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.13.11.52: indoleamine 2,3-dioxygenase

This is an abbreviated version!
For detailed information about indoleamine 2,3-dioxygenase, go to the full flat file.

Word Map on EC 1.13.11.52

Reaction

D-tryptophan
+
O2
=
N-formyl-D-kynurenine

Synonyms

31854, BRAFLDRAFT_126354, CG5163, EC 1.13.1.12, hIDO, hIDO1, hTDO, IDO, IDO-1, IDO-2, IDO-I, IDO-II, IDO-III, IDO-IV, IDO1, IDO2, INDO, INDOL1, indolamine 2,3-dioxygenase, indole 2,3-dioxygenase, indoleamine 2, 3-dioxygenase, indoleamine 2,3 dioxygenase, indoleamine 2,3-dioxygenase, indoleamine 2,3-dioxygenase 1, indoleamine 2,3-dioxygenase 2, indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2, indoleamine 2,3-dioxygenase-like protein, indoleamine-2,3-dioxygenase, Indoleamine-pyrrole 2,3-dioxygenase, L-tryptophan 2,3-dioxygenase, L-tryptophan pyrrolase, mIDO, oxygenase, tryptophan 2,3-di-, proto-IDO, proto-indoleamine 2,3-dioxygenase, superoxygenase, TDO, TDO2, TioF, TO, TRPO, Tryptamin 2,3-dioxygenase, tryptamine 2,3-dioxygenase, tryptophan 2,3-dioxygenase, tryptophan dioxygenase, tryptophan oxygenase, tryptophan peroxidase, tryptophan pyrrolase, tryptophan-2,3-dioxygenase, tryptophanase, v1g244579, Vermilion protein

ECTree

     1 Oxidoreductases
         1.13 Acting on single donors with incorporation of molecular oxygen (oxygenases)
             1.13.11 With incorporation of two atoms of oxygen
                1.13.11.52 indoleamine 2,3-dioxygenase

Inhibitors

Inhibitors on EC 1.13.11.52 - indoleamine 2,3-dioxygenase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(-)-kurarinone
non-competitive inhibitor
-
(10Z,13Z)-nonadecadienoic acid
-
32% inhibition at 0.02 mM
(11Z,14Z)-eicosadienoic acid
-
42% inhibition at 0.02 mM
(11Z,14Z,17Z)-eisosatrienoic acid
-
19% inhibition at 0.02 mM
(12Z,15Z)-heneicosadienoic acid
-
39% inhibition at 0.02 mM
(13Z,16Z)-docosadienoic acid
-
39% inhibition at 0.02 mM
(13Z,16Z,19Z)-docosatrienoic acid
-
52% inhibition at 0.02 mM
(1R,2S)-2-([[6-(trifluoromethyl)-1H-indazol-4-yl]amino]methyl)cyclohexan-1-ol
-
-
(1R,2S)-2-[[(5-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(5-bromo-1H-indazol-7-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(5-chloro-1H-indazol-7-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexyl acetate
-
-
(1R,2S)-2-[[(6-chloro-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(6-methyl-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1S,2R)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(2,4-dichlorophenyl)methanethiol
-
-
(2-chlorophenyl)methanethiol
-
-
(2E)-3-(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)prop-2-enoic acid
-
-
(2S)-2'-methoxy kurarinone
non-competitive inhibitor
-
(3,4-dichlorophenyl)methanethiol
-
-
(3-hydroxyphenyl)(phenyl)methanone
-
(3R,4S and 3S,4R)-3-bromo-4-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-3-hydroxy-2,2-dimethyl-4-morpholino-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-3-hydroxy-4-methoxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-4-(allylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-4-(benzylthio)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-3,4-dihydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
alpha-lapachone
(3S,4S and 3R,4R)-3-hydroxy-2,2-dimethyl-4-morpholino-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-3-hydroxy-4-methoxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-4-(allylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-4-(benzyloxy)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-4-(benzylthio)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S)-4-(benzylamino)-3,9-dihydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S)-4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(4-chlorophenyl)methanethiol
-
-
(4-chlorophenyl)methanol
-
-
(4-fluorophenyl)methanethiol
-
-
(4-methoxyphenyl)methanethiol
-
-
(4-methylphenyl)methanethiol
-
-
(4E,4'E)-4,4'-bis(isopropylimino)-2,2'-binaphthyl-1,1'-(4H,4'H)-dione
-
(4E,4'E)-4,4'-bis(pentan-3-ylimino)-2,2'-binaphthyl-1,1'-(4H,4'H)-dione
-
(4Z,7Z,10Z,13Z,16Z)-docosapentaenoic acid
-
48% inhibition at 0.02 mM
(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid
-
35% inhibition at 0.02 mM
(5Z,8Z)-7,7-dimethyl-5,8-eicosadienoic acid
-
29% inhibition at 0.02 mM
(5Z,8Z)-eicosadienoic acid
-
42% inhibition at 0.02 mM
(5Z,8Z,11Z)-eisosatrienoic acid
-
45% inhibition at 0.02 mM
(5Z,8Z,11Z,14Z)-eicosatetraenoic acid
-
55% inhibition at 0.02 mM; 80% inhibition at 0.02 mM
(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoic acid
-
19% inhibition at 0.02 mM
(7Z,10Z,13Z,16Z)-docosatetraenoic acid
-
42% inhibition at 0.02 mM
(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)boronic acid
-
-
(8Z,11Z,14Z)-eisosatrienoic acid
-
68% inhibition at 0.02 mM
(9E,11Z)-octadecadienoic acid
-
26% inhibition at 0.02 mM
(9E,12E)-octadecadienoic acid
-
23% inhibition at 0.02 mM
(9Z,12Z)-octadecadienoic acid
-
16% inhibition at 0.02 mM
(9Z,12Z,15Z)-octadecatrienoic acid
-
23% inhibition at 0.02 mM
(E)-4-(isopropylimino)-2-methylnaphthalen-1(4H)-one
-
(E)-6-fluoro-3-[2-(3-pyridyl)vinyl]-1H-indole
-
-
(R)-2-amino-N-(4-hydroxynaphth-1-yl)propanamide
-
(S)-2-amino-5-((R)-1-(carboxymethylamino)-3-(1,4-dihydroxy-3-methylnaphthalen-2-ylthio)-1-oxopropan-2-ylamino)-5-oxopentanoic acid
-
(S)-2-amino-5-((R)-1-(carboxymethylamino)-3-(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-ylthio)-1-oxopropan-2-ylamino)-5-oxopentanoic acid
-
(S)-2-amino-N-(4-hydroxynaphth-1-yl)propanamide
-
1,2-naphthoquinone
-
1,4-naphtho-quinone
-
1,6,6-trimethyl-10,11-dioxo-2-(thiophen-3-yl)-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl propanoate
0.02 mM, 29.3% inhibition
-
1,6,6-trimethyl-10,11-dioxo-2-phenyl-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl propanoate
0.02 mM, 21.5% inhibition
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl 1,3-thiazole-2-carboxylate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl acetate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl benzoate
0.02 mM, 54.5% inhibition
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl cyclohexanecarboxylate
0.02 mM, 48.0% inhibition
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl cyclopropanecarboxylate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl furan-3-carboxylate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl hydroxyacetate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl propanoate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl thiophene-2-carboxylate
0.02 mM, 60.4% inhibition
-
1,6,6-trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione
0.02 mM, 23.1% inhibition
1,6,6-trimethyl-6,7-dihydrophenanthro[1,2-b]furan-10,11-dione
0.02 mM, 61.2% inhibition
-
1,6,6-trimethylphenanthro[1,2-b]furan-7,10,11(6H)-trione
-
-
1,6,6-trimethylphenanthro[1,2-b]furan-9,10,11(6H)-trione
0.02 mM, 52.7% inhibition
-
1-(1,3-benzothiazol-2-ylsulfanyl)-N,N-dimethylmethanamine
-
1-(2-hydroxy-4-methylphenyl)-3-(2-methoxyphenyl)propane-1,3-dione
-
-
1-(2-hydroxy-4-methylphenyl)-3-{2-[(propan-2-yl)oxy]phenyl}propane-1,3-dione
-
-
1-(2-methylbenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-bromobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-bromothiophen-2-yl)-2-(3-methyl-1,4-dihydronaphthalen-2-yl)ethan-1-one
most potent inhibitor capable of blocking both indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO2) activity, with the IC50 value for BT-549 cells at 0.00342 mM
-
1-(3-chlorobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-[(4-acetyl-1-piperazinyl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-[(4-methyl-1-piperazinyl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-bromobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-bromophenyl)-2-[[5-(4-chlorophenyl)[1,3]thiazolo[2,3-c]-[1,2,4]triazol-3-yl]sulfanyl]ethanone
-
-
1-(4-chlorobenzyl)urea
-
-
1-(4-chlorophenyl)methanamine
-
-
1-(4-chlorophenyl)thiourea
-
-
1-(4-cyanophenyl)-3-(3-(cyclopropylethynyl)imidazo[2,1-b]thiazol-5-yl)thiourea
potent inhibitor. The basis for this high potency is a unique sulfur-aromatic interaction network formed by the thiourea moiety of the inhibitor with F163 and F226
-
1-(4-fluorobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-methylbenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-[(4-acetylpiperazin-1-yl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-[(4-methoxypiperidin-1-yl)carbonyl]benzyl)-1Hnaphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(hydroxymethyl)-6,6-dimethylphenanthro[1,2-b]furan-7,10,11(6H)-trione
-
-
1-(hydroxymethyl)-6,6-dimethylphenanthro[1,2-b]furan-9,10,11(6H)-trione
0.02 mM, 68% inhibition
-
1-benzofuran-DL-tryptophan
-
1 mM, 43% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
1-benzothiophene-DL-tryptophan
-
1 mM, 16% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
1-benzyl-5-phenyl-1H-imidazole
-
1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol
1-hydroxy-5,6-dimethoxy-3-oxo-2-phenyl-3H-indol-1-ium
-
1-L-methyltryptophan
1-methyl tryptophan
a tryptophan analogue. Galanal does not decrease the IkappaB-alpha expression in LPS-stimulated THP-1 cells
1-methyl-D-tryptophan
1-methyl-DL-Trp
1-methyl-DL-tryptophan
1-methyl-L-tryptophan
1-methyl-tryptophan
1-Methyltryptophan
1-oxo-2-phenyl-3H-1lambda5-indol-3-one
-
1-phenyl-2-(phenylsulfanyl)hydrazine
-
1-[(3-methylphenyl)methyl]-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-[(4-chlorophenyl)methyl]-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-3-carboxylic acid
-
-
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-4-carboxylic acid
-
-
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]proline
-
-
1-[2-(4-chlorophenyl)ethyl]thiourea
-
-
1-[3-(4-morpholinylcarbonyl)benzyl]-1H-naphtho[2,3-d]-[1,2,3]triazole-4,9-dione
-
1-[4-(morpholin-4-ylcarbonyl)benzyl]-1H-naphtho[2,3-d]-[1,2,3]triazole-4,9-dione
-
1-[4-[(4-methylpiperazin-1-yl)carbonyl]benzyl]-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-3-(4-methylphenyl)imidazolidin-2-one
-
-
15-deoxy-DELTA12,14-prostaglandin
-
-
1H-benzotriazole
-
-
1H-phenanthro[9,10-d]imidazole
-
2,1,3-benzothiadiazole
-
2,1,3-benzoxadiazole
-
2,2-dimethyl-1a,9b-dihydro-2H-benzo[g]oxireno[c]chromene-4,9-dione
-
2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
dehydro-alpha-lapachone
2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
2,2-dimethyl-3,4-epoxy-2H-naphtho[2,3-b]pyran-5,10-dione
-
2,3-dichloro-1,4-naphthoquinone
-
2,4-dichlorobenzyl carbamimidothioate hydrobromide
-
-
2-(1H-imidazol-4-yl)benzene-1,3-diol
-
2-(1H-imidazol-4-yl)benzenethiol
-
2-(1H-imidazol-4-yl)phenol
2-(1H-phenanthro[9,10-d]imidazol-2-yl)phenol
-
2-(1H-pyrazol-3-yl)phenol
-
2-(2-chlorophenyl)ethyl carbamimidothioate hydrobromide
-
-
2-(2-fluorophenyl)-1H-phenanthro[9,10-d]imidazole
-
2-(2-methylphenyl)-1-oxo-3H-1lambda5-indol-3-one
-
2-(2-methylphenyl)-1H-phenanthro[9,10-d]imidazole
-
2-(2-sulfanylidene-2,3-dihydro-1,3-thiazol-4-yl)benzoic acid
0.1 mM, 8% inhibition
-
2-(3-chlorophenyl)ethyl carbamimidothioate hydrobromide
-
-
2-(4-chlorophenyl)ethanamine
-
-
2-(4-chlorophenyl)ethyl carbamimidothioate hydrobromide
-
-
2-(4-methoxyphenyl)-1-oxo-3H-1lambda5-indol-3-one
-
2-(4-methoxyphenyl)-3H-indol-3-one
-
2-(4-methoxyphenyl)-3H-indole
-
2-(4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]-triazol-1-yl)methyl]phenyl)-N,N-diethylacetamide
-
2-([5-(3-methoxyphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)-N-(5-methyl-1,3-thiazol-2-yl)acetamide
F5H5G0, P14902
poor inhibitor; poor inhibitor
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (2-chlorophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (2-hydroxyphenyl)acetate
0.001 mM, 73% inhibition
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (2-nitrophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3,4-dihydroxyphenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3-chlorophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3-cyanophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3-hydroxyphenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3-nitrophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-chlorophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-cyanophenyl)acetate
0.001 mM, 69% inhibition
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-hydroxyphenyl)acetate
0.001 mM, 89% inhibition
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-nitrophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl phenylacetate
0.001 mM, 72% inhibition
-
2-amino-3-hydroxy-N-(4-hydroxynaphthalen-1-yl)propanamide
-
2-amino-N-(4-hydroxynaphth-1-yl)acetamide
-
2-bromo-4-phenyl-1,3-thiazole
0.1 mM, 12% inhibition
-
2-bromo-L-tryptophan
-
1 mM, 11% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
2-chloro-4-phenyl-1,3-thiazole
0.1 mM, 0.5% inhibition
-
2-chloro-L-tryptophan
-
1 mM, 20% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
2-chloro-N-[[(4-chlorophenyl)sulfanyl]methyl]aniline
-
2-chlorobenzyl carbamimidothioate hydrochloride
-
-
2-Hydroxy-1,4-naphthoquinone
-
2-hydroxy-L-tryptophan
-
1 mM, 30% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
2-hydroxygarveatin E
-
-
2-hydroxygarvin A
-
-
2-mercaptobenzothiazole
-
2-methoxy-1,4-naphthoquinone
-
2-methyl-1,4-naphthoquinone
-
2-methylindole
-
2-methylnaphthalene-1,4-dione
-
2-phenoxyaniline
-
2-phenyl-3H-indol-3-imine
-
2-phenyl-3H-indol-3-one
-
2-[(6-bromo-1H-indazol-4-yl)amino]-1-(3-chlorophenyl)ethan-1-ol
-
-
2-[(6-bromo-1H-indazol-4-yl)amino]-1-(4-hydroxyphenyl)ethan-1-one
-
-
2-[(6-bromo-1H-indazol-4-yl)amino]-2-(3-chlorophenyl)ethan-1-ol
-
-
2-[(6-bromo-1H-indazol-4-yl)amino]-2-phenylethan-1-ol
-
-
2-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoic acid
-
-
2-[[(2,4-dichlorophenyl)methyl]sulfanyl]-6-methylpyrimidin-4(5H)-one
-
2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
2-[[5-cyano-4-(3-methoxyphenyl)-6-oxo-1,6-dihydropyrimidin-2-yl]sulfanyl]-N-[5-(propan-2-yl)thiophen-2-yl]butanamide
0.01 mM, 24.4% inhibition
-
3'-[[(2-chlorophenyl)carbamoyl]amino]-4-methoxy-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
3'-[[(2-fluorophenyl)carbamoyl]amino]-4-methoxy-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[(2-methylpropyl)(propan-2-yl)amino][1,1'-biphenyl]-2-carboxylic acid
-
-
3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[(4aS,8aS)-octahydroquinolin-1(2H)-yl][1,1'-biphenyl]-2-carboxylic acid
-
-
3,4-dichlorobenzyl carbamimidothioate hydrochloride
-
-
3-(1H-1,2,3-triazol-5-yl)pyridine
3-(1H-imidazol-4-yl)benzaldehyde
-
3-(1H-imidazol-4-yl)benzenethiol
-
3-(1H-imidazol-4-yl)benzonitrile
-
3-(1H-imidazol-4-yl)phenol
-
3-(1H-phenanthro[9,10-d]imidazol-2-yl)phenol
-
3-(2-aminoethyl)-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 74.88% inhibition
-
3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazole
-
-
3-(4H-imidazol-4-yl)benzenethiol
-
3-chlorobenzyl carbamimidothioate hydrochloride
-
-
3-hydroxy-2,2-dimethyl-4-(morpholin-4-yl)-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
3-hydroxy-4-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
3-hydroxyanthranilic acid
-
-
3-hydroxykynurenine
3-indoleethanol
-
lowers Km value for D-tryptophan by 25% at pH 7, enhances Vmax by 40-60%
3-methyl-8-(4,4,4-trifluorobutoxy)-5H-indeno[1,2-c]pyridazin-5-one
-
31% inhibition at 0.025 mM
3-methyl-8-[(3-methylbenzyl)oxy]-5H-indeno[1,2-c]pyridazin-5-one
-
66% inhibition at 0.025 mM
3-phenylpyridine
-
3-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]-N,N-diethylbenzamide
-
3-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]benzoic acid
-
3-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoic acid
-
-
3-[2-(cyclohexylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 64.95% inhibition
-
3-[2-(diethylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 64.21% inhibition
-
3-[2-(dimethylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 71.26% inhibition
-
3-[2-(ethylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 81.67% inhibition
-
3-[2-(propylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 79.17% inhibition
-
3-[2-(tert-butylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 79.45% inhibition
-
3-[2-[(2-phenylethyl)amino]ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 68.26% inhibition
-
3-[2-[(propan-2-yl)amino]ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 63.75% inhibition
-
3-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]propanoic acid
EC50 is 183 nm
4'-(2,3-dimethylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-3'-([[4-(2-hydroxypropan-2-yl)phenyl]carbamoyl]amino)-4-methoxy[1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-3'-[[(4-chlorophenyl)carbamoyl]amino]-4-methoxy[1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-3'-[[(4-cyanophenyl)carbamoyl]amino]-4-methoxy[1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-4-methoxy-3'-[[(4-methoxyphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-ethylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylanilino)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-2-fluoro-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-4-chloro-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-4-ethoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-5-chloro-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(3-tert-butylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(cyclohexylamino)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-(dibutylamino)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-[(2,3-dihydro-1H-inden-4-yl)oxy]-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-[bis(2-methylpropyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-[bis(2-methylpropyl)amino]-N-(methanesulfonyl)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxamide
-
-
4'-[bis(cyclopropylmethyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-[cyclohexyl(methyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-[cyclopentyl(ethyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4-(1H-1,2,3-triazol-5-yl)pyridine
-
4-(1H-imidazol-4-yl)phenol
-
4-(1H-phenanthro[9,10-d]imidazol-2-yl)phenol
-
4-(2,6-dimethoxyphenyl)-1H-imidazole
-
4-(2-(diethylamino)ethylamino)-1-naphthol
-
4-(2-(methylthio)phenyl)-1H-imidazole
-
4-(2-fluorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 77% inhibition
-
4-(2-fluorophenyl)-1H-imidazole
-
4-(2-hydroxyethoxy)-1-naphthol
-
4-(2-methoxyphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 53% inhibition
-
4-(2-sulfanylidene-2,3-dihydro-1,3-thiazol-4-yl)benzonitrile
0.1 mM, 8% inhibition
-
4-(3-(methylthio)phenyl)-1H-imidazole
-
4-(3-bromophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 81% inhibition
-
4-(3-chlorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 40% inhibition
-
4-(3-chlorophenyl)-imidazole
-
-
4-(3-fluorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 28% inhibition
-
4-(3-fluorophenyl)-1H-imidazole
-
4-(4-(methylthio)phenyl)-1H-imidazole
-
4-(4-bromophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 100% inhibition
-
4-(4-chlorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 95% inhibition
-
4-(4-fluorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 72% inhibition
-
4-(4-fluorophenyl)-1H-imidazole
-
4-(4-methoxyphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 68% inhibition
-
4-(4-methylbenzene-1-sulfinyl)-7-nitro-2,1,3-benzoxadiazole
-
4-(4-methylphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 90% inhibition
-
4-(benzylamino)-1-naphthol
-
4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
4-(cyclohexylamino)-1-naphthol
-
4-(dimethylamino)naphthalen-1-ol
-
4-(ethylamino)-1-naphthol
-
4-(isobutylamino)-1-naphthol
-
4-(isopropylamino)-1-naphthol
-
4-(methanesulfonyl)-N'-(3-methylphenyl)benzene-1-sulfonohydrazide
EC5 is 7846 nm
4-(methylamino)naphthalen-1-ol
-
4-(pent-3-ylamino)-1-naphthol
-
4-(phenylcarbonyl)benzyl carbamimidothioate hydrobromide
-
-
4-(propan-2-yl)benzyl carbamimidothioate hydrobromide
-
-
4-(propylamino)-1-naphthol
-
4-(pyridin-3-yl)-1,3-thiazole-2(3H)-thione
0.1 mM, 48% inhibition
-
4-(pyridin-4-yl)-1,3-thiazole-2(3H)-thione
0.1 mM, 21% inhibition
-
4-(tert-butylamino)naphthalen-1-ol
-
4-(thiophen-2-yl)-1H-imidazole
-
4-(trifluoromethyl)benzyl carbamimidothioate hydrochloride
-
-
4-([[(1S,2R)-2-hydroxycyclohexyl]methyl]amino)-1H-indazole-6-carboxylic acid
-
-
4-amino-1,2,3-oxadiazole-3-carboximidamide
-
-
4-amino-1,2,5-oxadiazole-3-carboximidamide
-
competitive
4-amino-1-naphthol
-
4-amino-N'-hydroxy-N-(3-isopropylphenyl)-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N'-hydroxy-N-(3-methoxyphenyl)-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N'-hydroxy-N-(3-methylphenyl)-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N'-hydroxy-N-phenyl-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(2-chlorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-bromophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
4-amino-N-(3-chlorophenyl)-1,2,5-oxadiazole-3-carbohydrazonamide
-
-
4-amino-N-(3-chlorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-ethylphenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-tert-butylphenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(4-chlorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-benzyl-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-bromo-5-(4-methylphenyl)-1H-1,2,3-triazole
-
-
4-bromo-N'-(4-bromophenyl)benzene-1-sulfonohydrazide
EC50 is 374 nm
4-bromobenzyl carbamimidothioate hydrobromide
-
-
4-chloro-2-(1H-1,2,3-triazol-4-yl)phenol
i.e. MMG-0358
-
4-chlorobenzenesulfonic acid
-
-
4-chlorobenzenethiol
-
-
4-chlorobenzyl carbamimidothioate hydrochloride
-
-
4-chlorobenzyl N,N'-dimethylcarbamimidothioate - 1-chlorotetraoxidane (1:1)
-
-
4-chlorophenyl-1,2,3-triazol-4-amine
-
-
4-cyano-N'-(3-methylphenyl)benzene-1-sulfonohydrazide
EC50 is 3404 nm
4-cyanobenzyl carbamimidothioate hydrobromide
-
-
4-ethylbenzyl carbamimidothioate hydrochloride
-
-
4-fluoro-2-(1H-pyrazol-3-yl)phenol
-
4-fluorobenzyl carbamimidothioate hydrochloride
-
-
4-hydroxycarbazole
-
4-Hydroxypyrazole
-
-
4-iodo-5-phenyl-1H-1,2,3-triazole
-
-
4-methoxy-1-naphthylamine
-
4-methoxy-3'-[(phenylcarbamoyl)amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(2-methylphenyl)carbamoyl]amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(3-methylphenyl)carbamoyl]amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-(2-propylphenoxy)[1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[2-(propan-2-yl)phenoxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[2-methyl-3-[(prop-2-yn-1-yl)oxy]phenoxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxybenzyl carbamimidothioate hydrochloride
-
-
4-methyl-DL-tryptophan
-
1 mM, 26% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
4-methylbenzyl carbamimidothioate hydrochloride
-
-
4-nitro-2,1,3-benzothiadiazole
-
4-nitro-5-(4-nitrophenyl)-1H-1,2,3-triazole
-
-
4-nitro-7-[(1-oxo-1lambda5--pyridin-2-yl)sulfanyl]-2,1,3-benzoxadiazole
-
4-nitrobenzyl carbamimidothioate hydrochloride
-
-
4-phenyl-1,3-thiazol-2(3H)-one
0.1 mM, 15% inhibition
-
4-phenyl-1,3-thiazol-2-amine
4-phenyl-1,3-thiazole-2(3H)-thione
0.1 mM, 76% inhibition
-
4-phenyl-1,3-thiazole-2-thiol
-
4-phenyl-1H-imidazole
-
4-phenyl-imidazole
4-phenyl-imidazole coordinates transiently to the heme iron
4-phenylimidazole
4-tert-butylbenzyl carbamimidothioate hydrobromide
-
-
4-[(1Z)-2-[(6-bromo-1H-indazol-4-yl)amino]-N-hydroxyethanimidoyl]phenol
-
-
4-[(2,4-dichlorophenyl)sulfanyl]-7-nitro-2,1,3-benzoxadiazole
-
4-[(3-chlorophenyl)sulfanyl]-7-nitro-2,1,3-benzoxadiazole
-
4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]-N,N-diethylbenzamide
-
4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]benzoic acid
-
4-[(4-fluorophenyl)sulfanyl]-7-nitro-2,1,3-benzoxadiazole
-
4-[(4-methylphenyl)sulfanyl]-7-nitro-2,1,3-benzoxadiazole
-
4-[(carbamimidoylsulfanyl)methyl]benzoic acid hydrochloride
-
-
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzamide
-
-
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzene-1-sulfonamide
potent inhibitor with a moderate pharmacokinetic profile. 25% tumor growth inhibition and 30% reduction in tumor weight in a murine CT26 syngeneic model on day 18, with 100 mg/kg oral administration twice daily
-
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoic acid
-
-
4-[2-(4-bromophenyl)hydrazinesulfonyl]benzoic acid
EC50 is 172 nm
4-[2-(methylsulfanyl)phenyl]-1H-imidazole
-
4-[3-(hydroxymethyl)phenyl]-1,3-thiazole-2(3H)-thione
0.1 mM, 16% inhibition
-
4-[3-(methylsulfanyl)phenyl]-1H-imidazole
-
4-[4-(trifluoromethyl)phenyl]-1,3-thiazole-2(3H)-thione
0.1 mM, 37% inhibition
-
4-[[(2,4-dichlorophenyl)methyl]sulfanyl]-6-methylpyrimidin-2(1H)-one
-
4-[[(2,4-dichlorophenyl)methyl]sulfanyl]pyrimidin-2(1H)-one
-
4-[[(6-bromo-1H-indazol-4-yl)amino]methyl]phenol
-
-
5-(2-bromophenyl)-1H-1,2,3-triazole
-
-
5-(2-chlorophenyl)-1H-1,2,3-triazole
-
-
5-(2-fluorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 29% inhibition
-
5-(2-methoxyphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 12% inhibition
-
5-(2-methoxyphenyl)-1H-1,2,3-triazole
-
-
5-(3-bromophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 48% inhibition
-
5-(4-bromophenyl)-1H-1,2,3-triazole
-
-
5-(4-chlorophenyl)-1H-1,2,3-triazole
-
-
5-(4-chlorophenyl)-3-[(2-methylpropyl)sulfanyl][1,3]thiazolo-[2,3-c][1,2,4]triazole
-
-
5-(4-fluorophenyl)-1H-1,2,3-triazole
-
-
5-(4-methoxyphenyl)-1H-1,2,3-triazole
-
-
5-(4-methylphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 15% inhibition
-
5-(ethylamino)quinolin-8-ol
-
5-(isopropylamino)quinolin-8-ol
-
5-amino-8-hydroxyquinoline
-
5-benzyloxy-DL-tryptophan
-
1 mM, 2% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-bromo-DL-tryptophan
-
1 mM, 56% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-chloro-1,3-benzothiazole-2(3H)-thione
-
5-fluoro-DL-tryptophan
-
1 mM, 32% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-hydroxy-1,4-naphthoquinone
-
5-hydroxy-D-tryptophan
-
0.1 mM, 26% inhibition of cleavage of D-tryptophan, 29% inhibition of cleavage of L-tryptophan
5-hydroxy-L-Trp
-
5-hydroxy-L-tryptophan
5-hydroxyindole acetic acid
-
1 mM, 61.5% inhibition
5-hydroxytryptamine
-
1 mM, 82.3% inhibition
5-hydroxytryptophan
-
1 mM, 78.6% inhibition
5-methoxy-DL-tryptophan
-
1 mM, 35% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-methyl-DL-tryptophan
-
1 mM, 6% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-phenyl-1,3-thiazole-2(3H)-thione
0.1 mM, 16% inhibition
-
5-phenyl-1H-1,2,3-triazole
5-[(2E)-2-[(4-bromophenyl)methylidene]hydrazinyl]-1-(naphthalen-1-yl)tetrazolidine
0.01 mM, 54.3% inhibition
-
5-[[(2,4-dichlorophenyl)methyl]sulfanyl]-1H-1,2,4-triazole
-
6-(4-iodo-2-methylanilino)-2,1,3-benzoxadiazole-5-carboxylic acid
-
6-(4-iodo-2-methylanilino)-3-oxo-2,1,3lambda~5~-benzoxadiazole-5-carboxylic acid
-
6-bromo-1H-indazol-4-amine
-
-
6-bromo-N-(cyclohexylmethyl)-1H-indazol-4-amine
-
-
6-bromo-N-[(1,4-dioxaspiro[4.5]decan-6-yl)methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[(1R,2R)-2-hydroxycyclohexyl]-1H-indazole-4-carboxamide
-
-
6-bromo-N-[(pyridin-2-yl)methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[(pyrrolidin-3-yl)methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(1S,2R)-2-chlorocyclohexyl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(1S,2S)-2-chlorocyclohexyl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2R)-piperidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2R)-pyrrolidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2S)-piperidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2S)-pyrrolidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-fluoro-DL-tryptophan
-
1 mM, 54% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
6-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
6-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
6-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
6-methyl-DL-tryptophan
-
1 mM, 20% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
6-nitro-D-tryptophan
-
1 mM, 7% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
6-nitro-L-tryptophan
-
1 mM, competitive inhibition, 52% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
7-amino-2-[(2E)-3-(2H-1,3-benzodioxol-5-yl)prop-2-enoyl]-4-bromocyclohepta-2,4,6-trien-1-one
0.01 mM, 21.4% inhibition
-
7-fluoro-4-(2-fluoro-4-iodoanilino)-2,1,3-benzoxadiazole-5-carboxylic acid
-
7-hydroxy-1,6,6-trimethyl-6,7-dihydrophenanthro[1,2-b]furan-10,11-dione
-
-
7-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
7-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
7-methyl-DL-tryptophan
-
1 mM, 36% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
7-nitro-N-phenyl-2,1,3-benzoxadiazol-4-amine
-
8-(4,4,4-trifluorobutoxy)-3-[3-(trifluoromethyl)phenyl]-5H-indeno[1,2-c]pyridazin-5-one
-
20% inhibition at 0.025 mM
8-(benzyloxy)-3-[3-(trifluoromethyl)phenyl]-5H-indeno[1,2-c]pyridazin-5-one
-
-
8-fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolo[2,1-b]quinazoline-6,12-dione
-
-
8-fluoro-2-[(1H-1,2,3-triazol-1-yl)methyl]indolo[2,1-b]quinazoline-6,12-dione
-
-
8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazoline-2-carbaldehyde
-
-
8-fluorotryptanthrin
-
-
8-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
8-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
8-methoxy-3-[3-(trifluoromethyl)phenyl]-5H-indeno[1,2-c]pyridazin-5-one
-
18% inhibition at 0.025 mM
8-[(3-chlorobenzyl)oxy]-3-methyl-5H-indeno[1,2-c]pyridazin-5-one
-
19% inhibition at 0.025 mM
9-fluorenone
-
9-hydroxy-1,6,6-trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione
-
-
9-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
alpha-caryopterone
9-hydroxyfluorene
-
9-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
acetaminophen
-
no affect on holoenzyme, significant inhibition of apoenzyme, changes in brain serotonin levels due to inhibition of hepatic tryptophan 2,3-dioxygenase
actinomycin D
-
-
acyclovir
-
-
alpha-methyl-DL-tryptophan
-
1 mM, 1% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
alpha-N-methyl-L-tryptophan
-
1 mM, 33% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
annulin A
-
-
annulin B
antisense oligonucleotide A06007H
+G*+A*+T*T*G*T*C*C*A*G*G*A*+G*+T*+T, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06008H
+C*+T*+C*A*A*C*T*C*T*T*T*C*+T*+C*+G, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06030H
+A*+G*+G*C*G*C*T*G*T*G*A*C*T*+T*+G*+T, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06043H
+C*+C*+A*G*A*C*T*C*T*A*T*G*A*G*+A*+T*+C, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06044H
+G*+A*+G*A*T*G*A*T*C*A*A*T*G*C*+T*+G*+A, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06045H
+A*+G*+G*C*G*C*T*G*T*G*A*C*T*T*+G*+T*+G, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A07006H
+T*+G*+T*A*T*G*A*C*A*G*C*+C*+G*+T, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A07058H
+A*+T*+C*G*T*G*G*T*G*C*T*G*A*A*+C*+A*+A, (+) LNA-modified nucleotide, (*) PTO linkage
-
arachidonate
-
-
baicalein
-
uncompetitive reversible potent IDO-1 inhibitor
Bathocuproinesulfonate
-
competitive with respect to L-Trp and noncompetitive with respect to O2
benzophenone
-
Benzothiazole
NC503425
benzyl carbamimidothioate hydrochloride
-
-
Berberine
-
uncompetitive reversible potent IDO-1 inhibitor
beta-carboline
-
-
beta-Methyl-DL-tryptophan
-
1 mM, 7% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
brassinin
Cd2+
-
0.5-1.0 mM, non-competitive
Cinnabarinic acid
-
-
Cu2+
-
0.005 mM, 50% inhibition
cyanide
D-Trp
D-tryptophan
dexamethasone
Dichlorophene
-
diethyldithiocarbamate
DL-4-fluorotryptophan
DL-4-methyltryptophan
DL-5-fluorotryptophan
DL-5-hydroxytryptophan
-
1 mM, 55% inhibition
DL-5-Methyltryptophan
DL-alpha-methyltryptophan
-
-
epacadostat
-
epigallocatechin gallate
-
-
ethyl (2E)-3-(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)prop-2-enoate
-
-
ethyl 1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl (2E)-but-2-enedioate
-
-
ethyl 1-(4-chlorophenyl)-1H-1,2,3-triazole-4-carboxylate
-
-
exiguamine A
exiguamine B
-
-
ferricyanide
-
-
galanal
competitive inhibitor, IC50 value of 45 nM in the cell-based assay. galanal interfered with the transcriptional function of the nuclear factor-kappaB and the interferon-gamma signaling pathway. These effects of galanal are important for immune response. The inhibitory effect of galanal on IDO1 activity is stronger than that of 1-methyl tryptophan, a tryptophan analogue
gamma-glutamyl-S-(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)cysteinylglycine
-
garveatin A
-
-
garveatin C
-
-
garveatin E
-
-
hydroxylamine
hydroxylamine sulfate
-
0.1 mM causes 79% inhibition, 1 mM causes 94% inhibition
imidazole
-
negatively cooperative or competitive
imidodicarbonimidic diamide, N-methyl-N''-9-phenanthrenyl-, monohydrochloride
-
-
INCB024360
0.01 mM, 97.59% inhibition
-
indole
indole-3-acetic acid
-
1 mM, 19% inhibition of cleavage of D-tryptophan, 27% inhibition of cleavage of L-tryptophan
indole-3-acrylic acid
-
competitive inhibitor
Indole-3-propionic acid
-
-
Indolepropionic acid
interleukin-4
-
-
-
iodoacetic acid
-
1 mM, 12% inhibition of cleavage of D-tryptophan, 7% inhibition of cleavage of L-tryptophan
Jatrorrhizine
-
irreversible potent IDO-1 inhibitor
K3Fe(CN)6
-
1 mM, complete inhibition
kushenol E
non-competitive inhibitor, the inhibitor might be useful in the development of immunotherapeutic agents against cancers
kushenol F
non-competitive inhibitor
-
Kynurenic acid
-
0.1 mM, 57.2% inhibition. 1 mM, 99.4% inhibition
L-5-hydroxytryptophan
L-kynurenine
-
0.1 mM, 17.7% inhibition. 1 mM, 93.6% inhibition
L-Trp
-
above 8 mM
L-tryptophan
L-tryptophan ethyl ester
-
1 mM, 7% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
L-tryptophan methyl ester
-
1 mM, 30% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
levo-1-methyl tryptophan
-
-
menadione
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-3-carboxylate
-
-
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-4-carboxylate
-
-
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]prolinate
-
-
methyl 2-methyl-5,10-dioxo-5,10-dihydro-2H-benzo[g]chromene-2-carboxylate
-
methyl 3-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]propanoate
EC50 is 465 nm
methyl 4-([[(1S,2R)-2-hydroxycyclohexyl]methyl]amino)-1H-indazole-6-carboxylate
-
-
methyl 4-[(carbamimidoylsulfanyl)methyl]benzenesulfinate hydrobromide
-
-
methyl 7-fluoro-4-(2-fluoro-4-iodoanilino)-2,1,3-benzoxadiazole-5-carboxylate
-
methyl N-(4-chlorophenyl)carbamimidothioate hydroiodide
-
-
methyl N-[2-(4-chlorophenyl)ethyl]carbamimidothioate hydroiodide
-
-
methyl thiohydantoin-Trp
F5H5G0, P14902
-
methyl-thiohydantoin tryptophan
-
-
methyl-thiohydantoin-L-tryptophan
-
competitive inhibitor
methyl-thiohydantoin-tryptophan
-
limited selectivity towards indoleamine 2,3-dioxygenase
methylene blue
addition of methylene blue (0-0.1 mM) to NADPH-cytochrome P450 reductase-supported D-Trp incubations (with or without cytochrome b5) leads to concentration-dependent inhibition of IDO activity, addition of methylene blue (0-0.03 mM) to NADPH-cytochrome P450 reductase-supported L-Trp oxidation reactions results in a switch from substrate inhibition kinetics to Michaelis-Menten with increasing methylene blue concentration decreasing the affinity of IDO for L-Trp
methylthiohydantoin-DL-tryptophan
-
mitomycin C
-
-
N'-(3-methylphenyl)-4-[[5-(trifluoromethyl)pyridin-2-yl]oxy]benzene-1-sulfonohydrazide
EC50 is 296 nm
N'-(4-bromophenyl)-4-cyanobenzene-1-sulfonohydrazide
EC50 is 134 nm
N'-(4-bromophenyl)-4-methoxybenzene-1-sulfonohydrazide
EC50 is 640 nm
N'-(4-bromophenyl)benzenesulfonohydrazide
EC50 is 128 nm
N'-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-N-methyl-N-(4-methylphenyl)urea
-
-
N,N-dimethyl-1-[(4-phenyl-1,3-thiazol-2-yl)sulfanyl]methanamine
-
N-(1,3-benzodioxol-5-yl)-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
F5H5G0, P14902
a reversible inhibitor of IDO1. highly specific for IDO1 compared to IDO2, docking analysis with IDO1 and IDO2; a reversible inhibitor of IDO1. highly specific for IDO1 compared to IDO2, docking analysis with IDO1 and IDO2
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-1H-indole-2-carboxamide
-
-
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-4-bromo-1H-pyrrole-2-carboxamide
selective inhibitor of IDO1 against L-Trp dioxygenase (TDO) at 0.001 mM, yet when the concentration is increased up to 0.010 mM, an inhibition of TDO is observed to some extent
-
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-4-cyanobenzamide
-
-
N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-[[2-(sulfamoylamino)ethyl]amino]-1,2,5-oxadiazole-3-carboximidamide
-
-
N-(4'-[bis(2-methylpropyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-yl)-1,1,1-trifluoromethanesulfonamide
-
-
N-(4-bromophenyl)-7-nitro-2,1,3-benzoxadiazol-4-amine
-
N-(4-bromophenyl)-N'-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]urea
-
-
N-(4-chlorophenyl)-2H-1,2,3-triazol-4-amine
i.e. Vertex-AT
-
N-(4-hydroxy-1-naphthyl)ethane-1,2-diaminium chloride
-
N-(4-hydroxy-1-naphthyl)propane-1,3-diaminium chloride
-
N-(4-hydroxynaphthalen-1-yl)pyrrolidine-2-carboxamide
-
N-(4-methoxyphenyl)-7-nitro-2,1,3-benzoxadiazol-4-amine
-
N-(4-methylphenyl)-2,1,3-benzoxadiazol-4-amine
-
N-(4-methylphenyl)-7-nitro-2,1,3-benzoxadiazol-4-amine
-
N-(4-[2-[4-(trifluoromethyl)phenyl]hydrazinesulfonyl]phenyl)acetamide
EC50 is 181 nm
N-(4-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexylidene)hydroxylamine
-
-
N-(phenyldisulfanyl)aniline
-
N-acetyl-L-tryptophan
-
1 mM, 7% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
n-butyl isocyanide
-
heme ligand which binds tightly to the ferrous enzyme
N-carbamoyl-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
F5H5G0, P14902
poor inhibitor; poor inhibitor
N-ethylmaleimide
-
1 mM, 58% inhibition of cleavage of D-tryptophan, 45% inhibition of cleavage of L-tryptophan
N-methyl-L-Trp
F5H5G0, P14902
-
N-phenyl-p-phenylenediamine
-
N-[(1,3-benzothiazol-2-yl)sulfanyl]-2-nitrobenzene-1-sulfonamide
0.01 mM, 35.9% inhibition
-
N-[(azetidin-3-yl)methyl]-6-bromo-1H-indazol-4-amine
-
-
N-[(E)-(2-phenyl-3H-indol-3-yl)methylidene]hydroxylamine
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-3-methoxy-N-methylbenzamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-4-methoxy-N-methylbenzamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-N-(4-cyanophenyl)acetamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-N-methyl-4-nitrobenzamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-N-methylacetamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-N-phenylacetamide
-
-
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]-2,2-dimethylpropanamide
0.01 mM, 72.35% inhibition
-
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]acetamide
0.01 mM, 57.47% inhibition
-
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]benzamide
0.01 mM, 65.72% inhibition
-
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]benzenesulfonamide
0.01 mM, 59.71% inhibition
-
N-[4-(2-phenylhydrazinesulfonyl)phenyl]acetamide
EC50 is over 0.010 mM
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(2-methylphenyl)urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(3-methylphenyl)urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(4-methoxyphenyl)urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(4-methylphenyl)urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-phenylurea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-[4-(difluoromethoxy)phenyl]urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-[4-(trifluoromethoxy)phenyl]urea
-
-
N-[4-[2-(2,4-difluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is over 0.010 mM
N-[4-[2-(3,4-dichlorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 350 nm
N-[4-[2-(3,5-dichlorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 508 nm
N-[4-[2-(3,5-difluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 2229 nm
N-[4-[2-(3-bromo-4-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 2494 nm
N-[4-[2-(3-bromophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 7563 nm
N-[4-[2-(3-chloro-4-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 2588 nm
N-[4-[2-(3-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is over 0.010 mM
N-[4-[2-(3-methylphenyl)hydrazinesulfonyl]benzoyl]glycine
EC50 is 571 nm
N-[4-[2-(3-methylphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 241 nm
N-[4-[2-(4-bromo-3-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 187 nm
N-[4-[2-(4-bromo-3-methylphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 130 nm
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-chlorophenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-cyanophenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-fluorophenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-methoxyphenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-methylphenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(4-chlorophenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(4-methoxyphenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(4-methylphenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-butylurea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-cyclohexylurea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-[3-(1H-tetrazol-5-yl)phenyl]urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-[4-(1H-tetrazol-5-yl)phenyl]urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 85 nm
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]butanamide
EC50 is 187 nm
N-[4-[2-(4-chloro-3-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 84 nm
N-[4-[2-(4-chlorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 142 nm
N-[4-[2-(4-cyanophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 1393 nm
N-[4-[2-(4-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 609 nm
N-[4-[2-(4-methoxyphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is over 0.010 mM
N-[4-[2-(4-methylphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 1171 nm
N-[4-[2-(4-sulfamoylphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 3118 nm
N-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-2-(4-methylphenyl)acetamide
-
-
N-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-N'-(4-methylphenyl)urea
-
-
N-[[(1S,2R)-2-aminocyclohexyl]methyl]-6-bromo-1H-indazol-4-amine
-
-
N-[[(1S,2S)-2-aminocyclohexyl]methyl]-6-bromo-1H-indazol-4-amine
-
-
N-[[(4-chlorophenyl)sulfanyl]methyl]-2-nitroaniline
-
N-[[(4-chlorophenyl)sulfanyl]methyl]-4-methylaniline
-
N-[[(4-chlorophenyl)sulfanyl]methyl]-4-nitroaniline
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-2-hydroxyacetamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-4-oxobutanamide
0.001 mM, 97% inhibition
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-(phenylacetyl)glycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-(phenylacetyl)glycinamide
0.001 mM, 62% inhibition
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(2-nitrophenyl)acetyl]glycinamide
0.001 mM, 67% inhibition
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(3-nitrophenyl)acetyl]glycinamide
0.001 mM, 65% inhibition
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(4-nitrophenyl)acetyl]glycinamide
0.001 mM, 66% inhibition
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(2-chlorophenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(3,4-dihydroxyphenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(3-chlorophenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(3-hydroxyphenyl)acetyl]-N2-methylglycinamide
0.001 mM, 63% inhibition
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(4-chlorophenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(4-cyanophenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(4-hydroxyphenyl)acetyl]-N2-methylglycinamide
-
-
N1-acetyl-N2-formyl-5-methoxykynurenine
-
N2-[(2S)-2-amino-2-phenylacetyl]-N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]glycinamide
-
-
NADH
-
0.1 mM, 51.3% inhibition
NaN3
-
10 mM, 33% inhibition of cleavage of D-tryptophan, 32% inhibition of cleavage of L-tryptophan
naphthalene-1,4-diol
-
naphthalene-1,4-dione
-
NH2OH
nitric oxide
-
nitric oxide can potentially inhibit isozyme IDO2 activity
noranhydroicaritin
non-competitive inhibitor
norharman
norharmane
NHM, noncompetitive versus L-Trp and competitive versus O2
NSC 401366
-
competitive with respect to tryptophan
NSC275428
-
palmatine
-
irreversible potent IDO-1 inhibitor
phenylmethanethiol
-
-
potassium cyanide
-
-
primaquine
-
propan-2-yl 4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoate
-
-
prostaglandin (19R)-hydroxy-PGE2
-
-
prostaglandin 13,14-dihydro-15-oxo-PGE2
-
-
prostaglandin 15-oxo-PGE2
-
-
prostaglandin 15-oxo-PGF2alpha
-
-
prostaglandin 20-hydroxy PGE2
-
-
prostaglandin DELTA12-PGJ2
-
-
prostaglandin PGA2
-
-
prostaglandin PGD2
-
-
prostaglandin PGD2 ethanolamide
-
-
prostaglandin PGE2
-
-
prostaglandin PGE2 ethanolamide
-
-
prostaglandin PGF2beta
-
-
prostaglandin PGG2
-
-
prostaglandin PGH2
-
-
prostaglandin PGJ2
-
-
quinolin-8-ol
-
S-(2-chlorophenyl) (4-chlorophenyl)carbamothioate
-
serotonin
-
1 mM, 36% inhibition of cleavage of D-tryptophan, 37% inhibition of cleavage of L-tryptophan
sodium 4-chlorobenzenesulfinate
-
-
Sodium azide
sophoraflavanone B
non-competitive inhibitor
streptovaricin C
NSC19990
Superoxide dismutase
-
tenatoprazole
-
highly selective for IDO2 inhibition, no inhibition of IDO1 or tryptophan dioxygenase
tert-butyl 3-[[(6-bromo-1H-indazol-4-yl)amino]methyl]pyrrolidine-1-carboxylate
-
-
tert-butyl [2-(4,7-dioxo-5-phenyl-4,7-dihydro-1H-indol-3-yl)ethyl]carbamate
0.01 mM, 56.38% inhibition
-
tert-butyl [2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 66.51% inhibition
-
tert-butyl [2-[4,7-dioxo-5-(pyridin-4-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 12.42% inhibition
-
tert-butyl [2-[5-(2-fluorophenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 67.30% inhibition
-
tert-butyl [2-[5-(2-methoxyphenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 63.23% inhibition
-
tert-butyl [2-[5-(4-fluorophenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 43.34% inhibition
-
tert-butyl [2-[5-(4-methoxyphenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 34.45% inhibition
-
tert-butyl [2-[5-(4-methylphenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 25.52% inhibition
-
Thiourea
NSC201634
Tiron
transforming growth factor-beta
-
inhibits expression in skin and synovial fibroblasts
-
tryptamine
vitamin K3
menadione
xanthurenic acid
-
0.1 mM, 50.6% inhibition. 1 mM, 96.2% inhibition
[3-(4-bromobenzoyl)-1,2-oxazol-4-yl](naphthalen-2-yl)methanone
0.01 mM, 28.4% inhibition
-
[4-(1,4-dioxido-1,2,4-benzotriazin-3-yl)aminobutyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
[4-(1-oxido-1,2,4-benzotriazin-3-yl)aminobutyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenoxy]acetic acid
EC50 is 152 nm
[5-(1,4-dioxido-1,2,4-benzotriazin-3-yl)aminopentyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
[5-(1-oxido-1,2,4-benzotriazin-3-yl)aminopentyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
additional information
-